84
10.34
StockPurchaseAgreement datedDecember 17, 2008, among theRegistrant, IbisBiosciences, Inc. andAbbott
Molecular Inc. Portions of this exhibit have beenomitted and separately filedwith theSECwith a request for
confidential treatment. (23)
10.35
ResearchAgreement datedAugust 10, 2011between theRegistrant andCHDI Foundation, Inc. Portions of this
exhibit have beenomitted and separately filedwith theSECwith a request for confidential treatment. (3)
10.36
Amended andRestatedLicense andCollaborationAgreement among theRegistrant, Alnylam
Pharmaceuticals, Inc. andRegulus Therapeutics LLCdated January1, 2009. Portions of this exhibit have been
omitted and separately filedwith theSECwith a request for confidential treatment. (4)
10.37
AmendmentNo. 1 toAmended andRestatedLicenseAgreement between theRegistrant andOncoGenex
Technologies Inc. datedDecember 18, 2009. (24)
10.38
Amendment NumberOne to theAmended andRestatedLicense andCollaborationAgreement dated June 10, 2010
among theRegistrant, AlnylamPharmaceuticals, Inc. andRegulus Therapeutics Inc. Portions of this exhibit have
beenomitted and separately filedwith theSECwith a request for confidential treatment. (26)
10.39
SecondAmendment toLoanAgreement datedNovember 15, 2010between theRegistrant andRBSAsset
Finance, Inc. (22)
10.40
Development, Option andLicenseAgreement between theRegistrant andBiogen Idec InternationalHoldingLtd.
dated January3, 2012. Portions of this exhibit have beenomitted and separately filedwith theSECwith a request
for confidential treatment. (31)
10.41
ThirdAmendment toLoanAgreement dated June 24, 2012between theRegistrant andRBSAsset Finance, Inc.
(32)
10.42
DMPKResearch, Development, Option andLicenseAgreement between theRegistrant andBiogen IdecMA Inc.
dated June 27, 2012. Portions of this exhibit have beenomitted and separately filedwith the SECwith a request for
confidential treatment. (32)
10.43
LetterAgreement Amendment between theRegistrant andAlnylamPharmaceuticals, Inc. datedAugust 27, 2012.
Portions of this exhibit have beenomitted and separately filedwith theSECwith a request for confidential
treatment. (33)
10.44
Amendment #2 toResearch,Development andLicenseAgreement between theRegistrant andGlaxoGroup
Limited datedOctober 30, 2012. Portions of this exhibit have beenomitted and separately filedwith theSECwith
a request for confidential treatment. (37)
10.45
Collaboration, License andDevelopment Agreement between theRegistrant andAstraZenecaABdated
December 7, 2012. Portions of this exhibit have been omitted and separately filedwith the SECwith a request for
confidential treatment. (37)
10.46
NeurologyDrugDiscovery andDevelopment Collaboration, Option andLicenseAgreement between the
Registrant andBiogen IdecMA Inc. datedDecember 10, 2012. Portions of this exhibit have beenomitted and
separately filedwith the SECwith a request for confidential treatment. (37)
10.47
HTTResearch, Development, Option andLicenseAgreement among theRegistrant, F. Hoffmann-LaRocheLtd
andHoffman-LaRoche Inc. datedApril 8, 2013. Portions of this exhibit have beenomitted and separately filed
with theSECwith a request for confidential treatment. (35)
10.48
LetterAgreement between theRegistrant andCHDI Foundation, Inc. datedApril 8, 2013. Portions of this exhibit
have beenomitted and separately filedwith theSECwith a request for confidential treatment. (35)
10.49
StrategicNeurologyDrugDiscovery andDevelopment Collaboration, Option andLicenseAgreement between the
Registrant andBiogen IdecMA Inc. datedSeptember 5, 2013. Portions of this exhibit have beenomitted and
separately filedwith the SECwith a request for confidential treatment. (34)
